Navigation Links
NeurogesX Reports Third Quarter 2009 Results

ctively, based on weighted average shares outstanding of 17.6 million and 17.5 million, respectively.

Cash equivalents and short-term investments were approximately $57.0 million at September 30, 2009, compared to $13.4 million at June 30, 2009. The increase reflects the receipt of a $48.8 million upfront payment from Astellas received in July 2009.

Stephen Ghiglieri, CFO, commented, "The third quarter of 2009 represents the first time we have reported quarterly revenue, which marks a milestone for NeurogesX. Our balance sheet is also strongly positioned with $57 million in cash, cash equivalents and short term investments. Consistent with our spending guidance for 2009, we are continuing our conservative focus in advance of our upcoming PDUFA date. As a result of that focus, we have been investing in commercialization activities that require long lead times, such as setting up the distribution channel, that are necessary to implement now to be ready for our targeted first half 2010 launch. Major investments, such as sales force deployment, are still being deferred pending FDA approval of Qutenza. We are also exploring strategies to further strengthen our balance sheet ahead of a potential U.S. Qutenza launch."

Development Update

NeurogesX is advancing its planning for NGX-1998 and expects to re-initiate clinical development activities in 2010.

Conference Call Details

The Company will hold its quarterly conference call today at 9:00 a.m. ET (6:00 a.m. PT) to discuss third quarter 2009 results.

To participate, please dial 1-877-407-0789 (USA) or 1-201-689-8562 (International). To access the live web cast please visit the Investor Relations section on the corporate web site at

A replay of the conference call will be available beginning November 6, 2009 at 7:30 p.m. ET (4:30 p.m. PT) and endi

SOURCE NeurogesX
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. NeurogesX to Present at Two November Conferences
2. NeurogesX to Present at UBS Global Life Sciences Conference
3. NeurogesX to Present at Upcoming Fall Conferences
4. NeurogesX Appoints New Board Director and Audit Committee Chairman
5. NeurogesX Reports Second Quarter 2009 Results
6. NeurogesX Announces New PDUFA Date for Qutenza(TM) New Drug Application
7. NeurogesX to Hold Conference Call to Discuss Second Quarter 2009 Financial Results
8. NeurogesX Added to Russell 3000 Index
9. NeurogesX Provides U.S. Regulatory Update for Qutenza(TM)
10. NeurogesX to Present at Needham Life Sciences Conference
11. NeurogesX Receives European Commission Approval for Qutenza(TM)
Post Your Comments:
(Date:3/5/2015)... DIEGO , March 5, 2015  In response ... in Miami, FL on February ... are both of strong financial health and their SUDOSCAN® ... clinical research has indicated. Furthermore, Impeto prefers to have the ... There are more than 40 articles written by ...
(Date:3/4/2015)... , March 4, 2015 In an article ... UPMC Center for Health Security review the clinical aspects ... be used as bioweapons. The article, "Clinical Management of ... on the website of the New England Journal ... Eric Toner , and Tom Inglesby—review the clinical ...
(Date:3/4/2015)... Research and Markets ( ... "Global Biologics and Biosimilars Industry Report 2015" ... The Global Biologics and Biosimilars Industry Report 2015 ... current state of the biologics and biosimilars industry. ... of the industry including definitions, classifications, applications and ...
(Date:3/4/2015)... , March 4, 2015  BioClinica®, ... and technology provider, today announced that clinical ... countries convened at its annual European User ... to discuss the use of its ... BioClinica,s eClinical technologies include: the Microsoft Office-Smart ...
Breaking Biology Technology:Impeto Medical Responds to Published Allegations by LD Technology LLC ("LD") 2Latest Clinical Information On Bioterrorism Threats 2Global Biologics and Biosimilars Industry Report 2015-2020 2BioClinica Teams With Pharma To Tackle Clinical Trial Challenges In Europe 2BioClinica Teams With Pharma To Tackle Clinical Trial Challenges In Europe 3
... Researchers at North Carolina State University have created a ... which retains these properties under extremely high temperatures ... applications, such as engine components that are exposed to ... is made up of nanoscale crystals is far stronger ...
... PACS milestone is a testament to tight integration and ... ... Inc. (Nasdaq: AMCS ), a,leader in radiology and medical image ... Vision Series(TM),PACS at more than 100 facilities that use MEDITECH(TM) as ...
... /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex:,SVA), a leading ... the,Ministry of Health has purchased approximately RMB 20 ... vaccine, Healive(R), to,vaccinate people living in the disaster ... shipments of the Healive vaccine to,Sichuan, Shanxi and ...
Cached Biology Technology:AMICAS Announces Integrations at More Than 100 MEDITECH Facilities 2AMICAS Announces Integrations at More Than 100 MEDITECH Facilities 3Sinovac Receives RMB 20 Million Purchase Order for Healive from China's Ministry of Health to Vaccinate Earthquake Victims 2
(Date:2/19/2015)... , Feb .19, 2015 Research and Markets ... addition of the "Military Electro-Optical / Infrared ... Technology, by Platform - Forecast to 2020" ... military electro-optical/infrared systems market is expected to reach ... of 7.71%. This report segments the ...
(Date:2/11/2015)... 11, 2015 According ... Control Market by Product (Cards and Readers, Biometrics, Controllers, ... Government, Industrial, Healthcare, Education) and By Geography - Global Forecast and ... the Access Control Market is expected to ... a CAGR of 10.6% between 2014 and ...
(Date:2/5/2015)... , Jan. 26, 2015   Epic Sciences , ... cancer, today announced that Murali Prahalad , Ph.D., president ... Medicine World Conference (PMWC) 2015: Silicon Valley, which is ... Mountain View, Calif. on January 26-28, 2015. ... Come of Age as Biomarkers." Last year, Epic Sciences was ...
Breaking Biology News(10 mins):Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 2Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 3Access Control Market Worth $10.4 Billion by 2020 2Access Control Market Worth $10.4 Billion by 2020 3Access Control Market Worth $10.4 Billion by 2020 4Epic Sciences to Present at Personalized Medicine World Conference 2015 on the Use of Circulating Tumor Cells as Cancer Biomarkers 2
... sinister about epilepsy: the disease affects the very core ... lead to seizures throughout the body or in parts of ... possible. The causes are still only partially understood but ... or metabolic diseases have been implicated. Epilepsy is not ...
... February 1, 2013 Poor impulse control contributes ... rewarding substances, like food, alcohol, and other drugs. ... FDA-approved medications for alcoholism, like naltrexone (Revia) and ... by curbing cravings and creating unpleasant reactions to ...
... levels of greenhouse gases, particularly carbon dioxide (CO2), ... fuels, deforestation, cultivation of grasslands, drainage of the ... shifts in climate patterns have led scientists to ... and to develop methods to evaluate how changes ...
Cached Biology News:Cats and humans suffer from similar forms of epilepsy 2If you are impulsive, take modafinil and count to 10 2New protocol recommendations for measuring soil organic carbon sequestration 2New protocol recommendations for measuring soil organic carbon sequestration 3New protocol recommendations for measuring soil organic carbon sequestration 4
We offer solid and solution phase peptide synthesis including a whole range of modifications. Please send the details of your peptide synthesis need to
... Kit - Monolayer is a system designed for ... monolayer in a serum-free environment. The kit contains ... has been optimized for neural stem cell expansion ... & Development 10 :3129). Human fibroblast growth ...
... DNA Polymerase I from ... DNA polymerase. The enzyme also ... activities.1 The 5'?3' exonuclease activity ... nicks and gaps in the ...
... E. coli strain containing an overproducing ... M-MLV Reverse Transcriptase catalyzes the polymerization of ... hybrids(1). Full-length copies of large mRNAs, >10 ... has a much lower RNase H activity ...
Biology Products: